Invus Public Equities, L.P. 13D and 13G filings for Syros Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-12 4:30 pm Sale | 2024-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Invus Public Equities, L.P. | 1,063,829 3.800% | -2,587,372 (-70.86%) | Filing |
| 2024-11-12 4:30 pm Purchase | 2024-09-30 | 13G | Syros Pharmaceuticals, Inc. SYRS | Invus Public Equities, L.P. | 3,651,201 9.900% | 82,359 (+2.31%) | Filing |
| 2024-08-02 6:39 pm Purchase | 2024-07-25 | 13G | Syros Pharmaceuticals, Inc. SYRS | Invus Public Equities, L.P. | 3,568,842 9.900% | 3,568,842 (New Position) | Filing |